A Novel Biocompatible Cationic Liposome for the Delivery of Therapeutics
Web Published:
11/13/2020
A biocompatible liposome transfection agent
Lipid-based non-viral systems for gene transfer have been widely investigated over the past few decades. Compared with viral vectors, liposomal vectors have the advantages of easier mass production and less immunogenicity. Dr. Anthony Di Pasqua has developed a novel biocompatible cationic liposome for the delivery of various agents, including DNA therapeutics.
The PEGylated positively-charged liposome has been used to deliver a DNA payload and to release it over time in a biologically-relevant medium. This lipoplex exhibits significantly lower toxicity than commercially available agents such as jetPRIME, while demonstrating efficient internalization into the nucleus and DNA delivery.
https://www.pharmaceuticalonline.com/doc/an-introduction-to-liposome-processing-for-drug-delivery-0001
- Biocompatible: improved cell viability relative to commercially available lipofection agents.
- Efficient: validated efficient delivery of DNA cargo into cells and nuclei.
Patent Information:
| App Type |
Country |
Serial No. |
Patent No. |
Patent Status |
File Date |
Issued Date |
Expire Date |
|